ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 222

Viral Exposures As a Risk Factor for Rheumatoid Arthritis: Summarizing the Evidence

Fatima Kudaeva1, Janet E. Pope2 and Mark Speechley3, 1Department of Epidemiology & Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, 2Department of Medicine, University of Western Ontario, London, ON, Canada, 3Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, Western University, London, Canada, London, ON, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: meta-analysis, Rheumatoid arthritis (RA), risk and viruses

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Title: Epidemiology and Public Health Poster I: Rheumatoid Arthritis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease with a complex etiology. Infections are viewed as environmental triggers of RA.

Different viral exposures have been implicated in the etiology of RA via several mechanisms of immune activation, such as molecular mimicry. The purpose of this systematic review was to summarize the evidence relating to the association between putative viral exposures and RA.

Methods: A systematic literature search was conducted using MEDLINE-OVID, EMBASE-OVID, PUBMED and Cochrane library databases. Articles were included if they were case-controls, cross-sectional or cohort studies and were published in English.

Results: Of 6724 citations, 78 studies were selected for review, 48 were meta-analysed (Figure 1). Studies had poor quality. Based on the IgG antibodies and viral DNA, the odds of parvovirus B19 (PBV19) infection were increased in RA patients compared to controls (odds ratio (OR) (95%CI) = 1.77 (1.11; 2.80), p=0.02, OR (95% CI) = 3.53 (1.00; 12.53), p=0.05 for PVB19 IgG and DNA, respectively) (Figure 2). For Epstein-Barr virus (EBV), patients with RA had not significant OR of anti-Epstein-Barr nuclear antigen (EBNA) (N=17 studies, OR (95% CI) = 1.05 (0.79; 1.39), p = 0.75), but significant OR of anti-viral capsid antigen (VCA) (OR (95% CI) = 1.5 (1.07; 2.10), p=0.02) and anti-early antigen (EA) (OR (95% CI) = 2.74 (1.27; 5.94), p=0.01) (Figure 3). Cytomegalovirus (CMV) was not associated with RA (OR (95% CI) = 1.24 (0.78; 1.95), p=0.36). Chronic hepatitis B (HBV) was not associated with RA in 5 case-control (OR (95% CI) = 1.37 (0.83; 2.25, p=0.22) and 1 cohort studies (HR 1.09 (0.74, 1.63), p>0.05). Chronic hepatitis C (HCV) was associated with increased risk of RA in 7 case-control studies (OR (95% CI = 2.82 (1.35; 5.90, p=0.006) and 1 cohort study (HR 2.03 (1.27, 3.22), p<0.01). There is a risk of persistent arthritis after Chikungunya fever (OR (95% CI) = 90 (15.2; 134.3)).

Conclusion: Studies about the risk of RA after viral exposures suffer from inconsistent methodological quality. There is a risk of RA after PBV19 infection and possibly HCV but not EBV or HBV. Chikungunya virus is associated with the persistent inflammatory arthritis.

../../../../../../Desktop/ACR_2018/Figure%201.

../../../../../../Desktop/ACR_2018/Figure%202.

../../../../../../Desktop/ACR_2018/Figure%203.


Disclosure: F. Kudaeva, None; J. E. Pope, None; M. Speechley, None.

To cite this abstract in AMA style:

Kudaeva F, Pope JE, Speechley M. Viral Exposures As a Risk Factor for Rheumatoid Arthritis: Summarizing the Evidence [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/viral-exposures-as-a-risk-factor-for-rheumatoid-arthritis-summarizing-the-evidence/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/viral-exposures-as-a-risk-factor-for-rheumatoid-arthritis-summarizing-the-evidence/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology